clinical trial · NCT06217952
Safety, Tolerability, and Pharmacokinetics of SPL84 in Healthy Volunteers
Cystic FibrosisSPL84Placebo
brief summary
This Phase 1 study evaluated the safety, tolerability, and pharmacokinetics of SPL84 single ascending doses (SAD) in healthy volunteers (HV)
started
Feb 5, 2023
primary completion
Aug 6, 2023
completion
Aug 6, 2023
last updated
Jan 23, 2024
official title
A Phase 1, Randomized, Placebo-Controlled, Double Blind Single Ascending Dose Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of SPL84
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol